John R. Pinion II

John R. Pinion II

Chief Quality Officer and Executive Vice President, Translational SciencesatUltragenyx Pharmaceutical· In proxies 2021–2024

Pay in FY2024+2% from the year before · Ultragenyx Pharmaceutical stock -12.0% the same year

John R. Pinion II was paid $4.1M in FY2024 (Dec), up 2%. Ultragenyx Pharmaceutical stock fell 12.0% that year.

Pay$100 in the stock at the end of FY20 → $30
Pay is from the Summary Compensation Table of each Ultragenyx Pharmaceutical proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Ultragenyx PharmaceuticalPublic company · 5 yr
    • Chief Quality Officer and Executive Vice President, Translational Sciences2021 – Present · 5 yrStock in role -90%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?